Patents by Inventor Thomas R. Gadek

Thomas R. Gadek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190381136
    Abstract: This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 19, 2019
    Inventors: Gordon W. Laurie, Marc G. Odrich, Michelle Carpenter, Thomas R. Gadek, Paul A. Laskar
  • Patent number: 7259159
    Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: August 21, 2007
    Assignees: Sanofi-Aventis Deutschland GmbH, Genentech Inc.
    Inventors: Anuschirwan Peyman, David Will, Thomas R Gadek, Robert McDowell, Jean Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle
  • Patent number: 6872735
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: March 29, 2005
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Patent number: 6747148
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 8, 2004
    Assignees: Hoechst Marion Roussel Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6747016
    Abstract: The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonist and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or prolifertion of cells of the vascular smooth musculature.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: June 8, 2004
    Assignees: Aventis Pharma Deutschland GmbH, Genetech Inc.
    Inventors: Anuschirwan Peyman, Jochen Knolle, Thomas R Gadek, Jean-Francois Gourvest, Jean-Marie Ruxer
  • Patent number: 6743800
    Abstract: The present invention relates to compounds of formula (1), in which H, G, Z, X, Y, r, s and t have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (1) are valuable, pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: June 1, 2004
    Assignees: Aventis Pharma Deutschland GmbH, Genentech Inc.
    Inventors: Anuschirvan Peyman, Karl-Heinz Scheunemann, Thomas R Gadek, Jean-Francois Gourvest, Jean-Marie Ruxer
  • Publication number: 20040058968
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: July 11, 2003
    Publication date: March 25, 2004
    Applicant: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Patent number: 6667318
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: December 23, 2003
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Publication number: 20030203896
    Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.
    Type: Application
    Filed: January 27, 2003
    Publication date: October 30, 2003
    Inventors: Anurschirwan Peyman, David Will, Thomas R Gadek, Jochen Knolle, Robert McDowell, Jean-Francois Gourvest, Jean-Marie Ruxer
  • Patent number: 6602878
    Abstract: Acylquanidines of the formula wherein the substituents are defined as in the specification which are antagonists of the vitronectin receptor and inhibitors of cell adhesion and bone resorption mediated by the osteoclasts.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: August 5, 2003
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Jean-Marie Ruxer, Sarah C. Bodary
  • Patent number: 6586442
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and it prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: July 1, 2003
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6500815
    Abstract: The invention concerns compounds of formula (I) wherein: X, Y, R1, R2, Z, G are as defined in the description, the methods for preparing them and the intermediates in said method, their use as medicine and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 31, 2002
    Assignees: Aventis Pharma S.A., Genentech
    Inventors: Denis Carniato, Thomas R. Gadek, Jochen Knolle, Jean-Francois Gourvest, Anurschirwan Peyman, Sarah C. Bodary
  • Publication number: 20020187976
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 26, 2002
    Publication date: December 12, 2002
    Applicant: Aventis Pharma S.A.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah Bodary, Thomas R. Gadek
  • Publication number: 20020172967
    Abstract: Methods for identifying novel drug leads or binding compounds that have an affinity for a target molecule involving screening known drug fragment molecules and derivatives thereof, preferably using mass spectrometry are disclosed.
    Type: Application
    Filed: February 12, 2002
    Publication date: November 21, 2002
    Inventors: Thomas R. Gadek, Denise Ockey
  • Patent number: 6458801
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and its prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary
  • Patent number: 6459001
    Abstract: The subject of the invention is the products of formula (I): in which R1, R2, R3, R4, R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genetech
    Inventors: Serge Bernard, Denis Carniato, Jean-Francois Gourvest, Jean-Georges Teutsch, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Sarah C. Bodary, Thomas R. Gadek, Robert S. McDowell, Robert M. Pitti
  • Publication number: 20020119994
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: November 26, 2001
    Publication date: August 29, 2002
    Applicant: GENENTECH, INC
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Publication number: 20020065271
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Application
    Filed: October 9, 2001
    Publication date: May 30, 2002
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert Mcdowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Patent number: 6391904
    Abstract: A compound of the formula where the substituents are defined in the specification and its pharmaceutically acceptable salts and prodrugs thereof useful as antagonists of vitronectin receptors.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 21, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6387395
    Abstract: This invention relates to compounds of the formula or an optical isomer thereof wherein R1 and R2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R3, R4 and R5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R3, R4, and R5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: May 14, 2002
    Inventors: Deborah A. Eppstein, Philip L. Felgner, Thomas R. Gadek, Gordon H. Jones, Richard B. Roman